SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001798749-23-000023
Filing Date
2023-04-05
Accepted
2023-04-05 16:32:36
Documents
15
Period of Report
2023-04-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tmb-20230405x8k.htm   iXBRL 8-K 47900
2 EX-5.1 tmb-20230405xex5d1.htm EX-5.1 13441
3 EX-10.1 tmb-20230405xex10d1.htm EX-10.1 283625
4 GRAPHIC tmb-20230405xex5d1001.jpg GRAPHIC 6164
  Complete submission text file 0001798749-23-000023.txt   547425

Data Files

Seq Description Document Type Size
5 EX-101.SCH tmb-20230405.xsd EX-101.SCH 3122
6 EX-101.LAB tmb-20230405_lab.xml EX-101.LAB 16576
7 EX-101.PRE tmb-20230405_pre.xml EX-101.PRE 10778
9 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20230405x8k_htm.xml XML 4990
Mailing Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451
Business Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

IRS No.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40544 | Film No.: 23803024
SIC: 2834 Pharmaceutical Preparations